...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Any day now......
2
May 27, 2021 01:24PM
1
May 28, 2021 11:44AM
7
May 28, 2021 12:15PM
1
May 28, 2021 12:25PM
1
May 28, 2021 12:30PM
1
May 28, 2021 12:35PM
2
May 28, 2021 12:36PM
5
May 28, 2021 12:55PM
5
May 28, 2021 12:57PM
1
May 28, 2021 01:34PM
3
May 28, 2021 02:19PM
6
May 28, 2021 02:47PM
2
May 28, 2021 04:20PM
1
May 28, 2021 04:34PM
1
May 28, 2021 04:51PM
6
May 28, 2021 05:05PM

May 28, 2021 05:27PM
1
May 28, 2021 06:30PM
1
May 28, 2021 08:14PM
1
May 28, 2021 08:33PM

May 28, 2021 08:42PM
3
May 28, 2021 09:29PM
6
May 28, 2021 10:15PM
2
May 28, 2021 11:05PM

I found the Control No. 250480 for this trial in the ‘No Objection’ letter. Search by this Control No. on this site https://health-products.canada.ca/ctdb-bdec/search-recherche.do and you will get the information that I have copied below.

 

Clinical trial information

From Health Canada

New search

Medical condition:

CORONAVIRUS DISEASE (COVID-19)

Study population:

ADULT FEMALE, ADULT MALE

Drug name:

RVX000222 (APABETALONE)

Protocol title:

AN OPEN-LABEL STUDY TO ASSESS THE SAFETY AND EFFECT ON CLINICAL COURSE AND KEY BIOMARKERS OF ORAL APABETALONE IN HOSPITALIZED SUBJECTS WITH COVID-19 INFECTION IN ADDITION TO STANDARD OF CARE (SOC)

Protocol number:

RVX222-CS-023

Sponsor name:

RESVERLOGIX CORP

Date of no objection letter:

2021-04-06

Control number:

250480

Trial status:

PENDING

Date study started:

Date study completed:


Jun 01, 2021 11:46AM
2
Jun 01, 2021 12:27PM
5
Jun 01, 2021 02:10PM
6
Jun 01, 2021 03:14PM
Share
New Message
Please login to post a reply